仿真基础设施平台开发商Inner Logic完成1150万美元种子轮融资，用于构建程序化设备实现自主的基础设施-动脉网

Inner Logic Raises $11.5 Million Seed Round | MitoSense and Aquila Health Enter Strategic Partnership

Healthcare IT Today 等信源发布 2026-07-23 21:12



可切换为仅中文







Check out today’s featured companies who have recently raised a round of funding, and be sure to check out the full list of past

查看今日精选的近期完成一轮融资的公司，并务必查看完整的过往列表

healthcare IT fundings

医疗IT融资

。

Inner Logic Raises $11.5 Million Seed Round to Build Autonomy-Enabling Infrastructure for Procedural Devices

Inner Logic 完成1150万美元种子轮融资，旨在为程序化设备构建赋能自主性的基础设施

Inner Logic

内部逻辑

(formerly Semaphor) today announced an $11.5 million seed round co-led by General Catalyst and Bison Ventures with participation from J2VP, Defined, PTX, Valia Ventures, Page One, Alumni Ventures, and Flare. Inner Logic gives device manufacturers the infrastructure to design, test, and validate procedural devices across thousands of virtual patients and procedures before clinical deployment.

（前身为 Semaphor）今日宣布完成由 General Catalyst 和 Bison Ventures 联合领投、J2VP、Defined、PTX、Valia Ventures、Page One、Alumni Ventures 和 Flare 参与的 1150 万美元种子轮融资。Inner Logic 为设备制造商提供基础设施，使其能够在临床部署之前，针对数千名虚拟患者和手术场景设计、测试并验证介入类医疗器械。

The same infrastructure provides the capabilities needed to make surgical autonomy a reality..

相同的基础设施为实现手术自主提供了所需的能力。

“Surgery is on the same path as autonomous driving, which became real once the industry built the simulation and data systems to show a car could drive itself. At Inner Logic, we are building that layer for all of procedural medicine, starting with the way devices are designed and tested. When device makers can develop and prove intelligent systems this way, the quality of a patient’s care stops depending on which hospital they can access or which surgeon is on call,” said Tito Porras, MD, Co-Founder and CEO at Inner Logic..

“外科手术与自动驾驶走在同一条道路上。一旦行业构建起仿真和数据系统，证明汽车可以自主驾驶，自动驾驶便成为现实。在Inner Logic，我们正在为整个程序化医疗领域构建这一基础层，从医疗器械的设计和测试方式入手。当设备制造商能够以这种方式开发并验证智能系统时，患者所接受的护理质量将不再取决于他们能进入哪家医院或哪位外科医生值班。”Inner Logic联合创始人兼首席执行官Tito Porras医学博士表示。

Inner Logic was co-founded by CEO Tito Porras, MD, who left his neurosurgery residency at Johns Hopkins Hospital to build the company; CTO Mathias Unberath, PhD, an award-winning computer vision and simulation researcher at Johns Hopkins Whiting School of Engineering; and Chief Robotics Officer Axel Krieger, PhD, an associate professor at Johns Hopkins Whiting School of Engineering, whose robot performed the first autonomous laparoscopic surgery in a live animal.

Inner Logic 由首席执行官兼医学博士 Tito Porras、首席技术官兼哲学博士 Mathias Unberath，以及首席机器人官兼哲学博士 Axel Krieger 联合创立。Tito Porras 离开了约翰斯·霍普金斯医院的神经外科住院医师培训项目以创建该公司；Mathias Unberath 是约翰斯·霍普金斯大学怀廷工程学院屡获殊荣的计算机视觉与仿真研究员；Axel Krieger 是约翰斯·霍普金斯大学怀廷工程学院的副教授，其研发的机器人完成了首例活体动物自主腹腔镜手术。

Together, the founders have authored more than 400 peer-reviewed publications and are named inventors on over 40 patents..

两位创始人共同撰写了400多篇经过同行评审的出版物，并且是超过40项专利的命名发明人。

Today, much of the exploratory work in device development still happens in the physical world. Teams build prototypes, test them in cadaver labs or animal studies, and learn what works, one experiment at a time. Each iteration is expensive and covers only a narrow slice of the patients a device will encounter.

如今，设备开发中的大量探索性工作仍然在物理世界中进行。各团队构建原型，在尸体实验室或动物研究中对其进行测试，并通过一次次实验来验证哪些方法可行。每次迭代成本高昂，且仅能覆盖该设备将来会面对的患者群体中极小的一部分。

What one program learns rarely carries into the next..

一个程序所学到的内容很少能延续到下一个程序中。

Inner Logic moves that work into simulation, where device teams can design and test across thousands of virtual patients overnight. Those virtual patients are built from real clinical and procedural data, so what teams learn in simulation holds up in the physical world…

Inner Logic 将这项工作整合到仿真环境中，使设备团队能够在一夜之间针对数千名虚拟患者进行设计和测试。这些虚拟患者基于真实的临床和手术数据构建，因此团队在仿真中获得的经验在现实世界中同样适用……

Full release here

完整版本在此

, originally announced July 22nd, 2026.

，最初于2026年7月22日宣布。

MitoSense and Aquila Health Enter Strategic Partnership to Build AI-Ready Data Infrastructure for Mitochondrial Medicine

MitoSense与Aquila Health达成战略合作伙伴关系，为线粒体医学构建面向人工智能的数据基础设施

Built on Aquila’s TREUE Standard, the Collaboration will Create a Governed, Longitudinal Data Foundation for Mitochondrial Medicine

基于Aquila的TREUE标准，该合作将为线粒体医学创建一个受治理的纵向数据基础

MitoSense, Inc.

MitoSense 公司

, a biotechnology company developing therapies that restore function for neurodegenerative, metabolic, and other diseases linked to mitochondrial dysfunction, today announced a strategic partnership with

，一家致力于开发恢复线粒体功能障碍相关的神经退行性疾病、代谢性疾病及其他疾病功能的疗法的生物技术公司，今日宣布与

Aquila Health PBC

阿奎拉健康公益公司

, a healthcare data infrastructure company, to create an artificial intelligence-ready data foundation for its research, future clinical programs, and commercial activities. The collaboration is expected to help researchers better understand disease progression and treatment response in conditions such as ALS, Parkinson’s disease, Alzheimer’s disease, Long COVID, and HIV..

，一家医疗数据基础设施公司，为其研究、未来临床项目及商业活动打造面向人工智能的数据基础。此次合作有望帮助研究人员更好地理解肌萎缩侧索硬化症（ALS）、帕金森病、阿尔茨海默病、长新冠和艾滋病等疾病的进展及治疗反应。

As MitoSense’s strategic partner, Aquila will use its TREUE standard to create a governed, complete patient view by connecting fragmented healthcare data across systems. This addresses a central challenge in advanced medicine: researchers cannot fully understand

作为MitoSense的战略合作伙伴，Aquila将利用其TREUE标准，通过连接跨系统的碎片化医疗数据，构建一个受治理的、完整的患者全景视图。这解决了先进医学领域的一个核心挑战：研究人员无法全面理解

disease progression, treatment response, and long-term outcomes

疾病进展、治疗反应和长期结果

without understanding the whole patient. Despite healthcare generating enormous volumes of data, an estimated

在不全面了解患者的情况下。尽管医疗保健产生了海量的数据，据估计

97%

goes unused, leaving researchers with incomplete patient records that make it difficult to gain a multi-dimensional understanding of patient health over time.

未被使用，导致研究人员手中的患者记录不完整，难以随时间推移对患者健康状况形成多维度的理解。

For an emerging field such as mitochondrial medicine, this is particularly critical, as patient response may be shaped by medications, therapies, coexisting conditions, organ function, inflammation, metabolism, immune response, and long-term disease progression. For example, if a patient with

对于线粒体医学这样一个新兴领域，这一点尤为关键，因为患者的反应可能受到药物、疗法、共存疾病、器官功能、炎症、代谢、免疫反应以及长期疾病进展的影响。例如，如果一名患有

ALS

肌萎缩侧索硬化症

experiences slower disease progression, or a patient with

疾病进展较慢，或一名患有

Alzheimer’s

阿尔茨海默病

disease demonstrates changes in cognitive function during a future clinical study, researchers need to understand whether those outcomes are associated with the investigational therapy or influenced by other medications, underlying conditions, or unrelated clinical factors. Without that context, important signals can be missed or clinical outcomes misinterpreted..

如果疾病在未来的临床研究中表现出认知功能的变化，研究人员需要了解这些结果是否与研究中的疗法相关，还是受到其他药物、基础疾病或无关临床因素的影响。如果没有这种背景信息，可能会遗漏重要的信号或误解临床结果。

“Mitochondrial medicine will require a new kind of data backbone,” said

“线粒体医学将需要一种新型的数据骨干，”

Van Hipp, Chairman at MitoSense

范·希普，MitoSense 董事长

. “We are working in an area where patient history, medications, biomarkers, safety signals, clinical outcomes, and long-term follow-up all matter. To understand whether a patient is improving, stable, or experiencing a setback, we need to understand the whole patient, including what other drugs or therapies may be affecting their health.

“我们在一个患者病史、用药情况、生物标志物、安全性信号、临床结局以及长期随访都至关重要的领域开展工作。为了判断患者是在改善、保持稳定还是出现病情反复，我们需要全面了解患者的整体状况，包括其他药物或疗法可能对其健康产生的影响。”

Aquila brings the governed, AI-ready infrastructure needed to connect those pieces responsibly. This partnership is about making sure the data foundation is ready for the science.”.

Aquila 提供了治理完善、面向 AI 的基础设施，以负责任地连接这些组件。此次合作旨在确保数据基础为科学研究做好准备。

Rather than requiring healthcare organizations to move sensitive patient information into a centralized repository, Aquila securely connects data where it already resides, allowing researchers to generate insights while organizations maintain control of their data. The companies will continue to evaluate how Aquila’s TREUE standard and related AI capabilities support MitoSense’s clinical research, outcome analytics, data management initiatives, and future project-based engagements.

Aquila 无需医疗机构将敏感的患者信息迁移至集中式存储库，而是安全地连接数据所在的原位，使研究人员能够在机构保持数据控制权的同时生成洞察。双方公司将持续评估 Aquila 的 TREUE 标准及相关人工智能能力如何支持 MitoSense 的临床研究、结果分析、数据管理举措以及未来基于项目的合作。

In time, the AI data foundation is expected to help MitoSense identify meaningful .

随着时间的推移，AI数据基础预计将帮助MitoSense识别出有意义的内容。

biomarkers, monitor safety, and generate the evidence needed to advance development of treatment programs

生物标志物、监测安全性，并生成推动治疗方案开发所需的证据

。

Aquila is led by

Aquila 由……领导

Dr. Jaime Bland, DNP, RN

杰米·布兰德博士，护理实践博士，注册护士

, Co-Founder and Chief Executive Officer. Dr. Bland previously served as President and CEO of CyncHealth, where she helped build and operate a multi-state health information exchange network supporting data coordination across more than six million lives.

，联合创始人兼首席执行官。Bland 博士此前曾担任 CyncHealth 的总裁兼首席执行官，在那里她帮助构建并运营一个跨州的健康信息交换网络，支持超过六百万人口的数据协调工作。

“Healthcare does not suffer from a lack of data. It suffers from fragmented data that cannot be used together responsibly,” said

“医疗行业并不缺乏数据，而是受困于无法负责任地整合使用的碎片化数据，”

Dr. Jaime Bland, Co-Founder and CEO at Aquila Health PBC

海梅·布兰德博士，Aquila Health PBC 联合创始人兼首席执行官

. “MitoSense is advancing science that will require longitudinal, multi-source evidence across clinical, laboratory, biomarker, medication, and outcome data. Aquila was built to make that kind of data usable, secure, governed, and ready for advanced analytics without forcing organizations into a single centralized warehouse.

“MitoSense 正在推进科学研究，这需要跨越临床、实验室、生物标志物、药物和结果数据的纵向、多源证据。Aquila 的构建旨在使此类数据可用、安全、受治理并准备好进行高级分析，而无需迫使组织采用单一集中式数据仓库。”

We are excited to work with MitoSense to explore how our infrastructure can support clinical research, translational science, and future evidence generation.”.

我们很兴奋能与 MitoSense 合作，探索我们的基础设施如何支持临床研究、转化科学以及未来的证据生成。

MitoSense is currently advancing preclinical and regulatory groundwork towards Phase 1 clinical trials, with Aquila’s AI data infrastructure planned to support future studies through the mitochondrial medicine platform.

MitoSense 目前正在推进临床前研究和监管准备工作，以期进入一期临床试验；Aquila 的人工智能数据基础设施计划通过线粒体药物平台为未来研究提供支持。

About MitoSense

关于 MitoSense

MitoSense, Inc. is a biotechnology company focused on mitochondrial health and mitochondrial organelle transplantation technologies. The company is developing platforms intended to study and address mitochondrial dysfunction across high-impact translational applications, including neurodegenerative disease, post-viral syndromes, and other conditions where impaired cellular energy may play an important role.

MitoSense, Inc. 是一家专注于线粒体健康和线粒体细胞器移植技术的生物技术公司。该公司正在开发旨在研究和解决线粒体功能障碍的平台，涵盖高影响力的转化应用领域，包括神经退行性疾病、病毒感染后综合征以及其他细胞能量受损可能发挥重要作用的疾病。

MitoSense is also building a growing network of scientific, clinical, patient-advocacy, and translational relationships, including collaborations and engagements with James A. Haley Veterans; Hospital, Walter Reed Army Institute of Research (WRAIR) through Cooperative Research and Development, Agreements (CRADAs), Greenwood Genetic Center, and Hop On a Cure.

MitoSense 还在不断拓展其科学、临床、患者倡导和转化关系网络，包括与詹姆斯·A·哈利退伍军人医院、通过合作研发协议（CRADAs）与沃尔特·里德陆军研究所（WRAIR）、格林伍德遗传中心以及 Hop On a Cure 组织的合作与互动。

These relationships support MitoSense’s strategy of advancing mitochondrial science through disciplined research partnerships, patient- centered insight, and real-world evidence generation, focused on specific clinical, longevity, or anti-aging outcomes in the future. For more information, please visit .

这些合作关系支持 MitoSense 通过严谨的研究伙伴关系、以患者为中心的洞察以及真实世界证据生成，推动线粒体科学发展的战略，未来将聚焦于特定的临床、长寿或抗衰老成果。欲了解更多信息，请访问。

mitosense.com

。

About Aquila Health PBC

关于 Aquila Health PBC

Aquila Health PBC is a Delaware public benefit corporation focused on healthcare data infrastructure, artificial intelligence, information exchange governance, and population health analytics. Its TREUE platform is designed to normalize and mobilize fragmented health data across organizations, systems, and geographies, enabling longitudinal, multi-source data integration for research, clinical decision-making, public health, and regulated healthcare environments.

Aquila Health PBC 是一家特拉华州的公益公司，专注于医疗数据基础设施、人工智能、信息交换治理以及人群健康分析。其 TREUE 平台旨在标准化并激活跨组织、系统和地域的碎片化健康数据，从而实现面向研究、临床决策、公共卫生及受监管医疗环境的纵向多源数据整合。

For more information, please visit .

更多信息，请访问。

aquilahealth.com

。

Originally announced July 21st, 2026.

最初于2026年7月21日宣布。